DiaMedica Therapeutics (NASDAQ:DMAC) Posts Earnings Results, Beats Estimates By $0.02 EPS

DiaMedica Therapeutics (NASDAQ:DMAC) posted its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02, FiscalAI reports.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC traded down $0.15 during mid-day trading on Monday, hitting $6.64. The company had a trading volume of 343,958 shares, compared to its average volume of 218,931. DiaMedica Therapeutics has a 12 month low of $3.19 and a 12 month high of $10.42. The firm has a market cap of $345.79 million, a P/E ratio of -9.35 and a beta of 1.09. The business’s 50-day simple moving average is $7.90 and its 200-day simple moving average is $7.66.

Analyst Upgrades and Downgrades

Several research analysts have commented on DMAC shares. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Institutional Trading of DiaMedica Therapeutics

Hedge funds have recently modified their holdings of the company. Invesco Ltd. increased its position in shares of DiaMedica Therapeutics by 29.9% during the fourth quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock valued at $148,000 after purchasing an additional 4,293 shares during the period. XTX Topco Ltd bought a new position in DiaMedica Therapeutics in the fourth quarter worth $234,000. Wellington Management Group LLP acquired a new stake in DiaMedica Therapeutics during the fourth quarter worth $825,000. Quadrature Capital Ltd bought a new stake in DiaMedica Therapeutics in the 4th quarter valued at $188,000. Finally, Balyasny Asset Management L.P. bought a new stake in DiaMedica Therapeutics in the 4th quarter valued at $136,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.